MarketLens

Fennec Pharmaceuticals: Is PEDMARK's Q1 2026 Performance a Game Changer

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Chesapeake Utilities (CPK) Q1 2026 Performance a Game Changer for Investors

3 months ago

What Drove Neo Performance Materials' Record Q1 2026 Performance

3 months ago

What's Driving ARS Pharmaceuticals' Q1 2026 Earnings Narrative

3 months ago

What's Driving Regional Bank Performance in Q1 2026

4 months ago

Adherex Technologies Q2 Earnings Call Highlights

Fennec Pharmaceuticals (Adherex Technologies) reported Q2 2026 net product sales of $17.1 million, up ~78% from $9.7 million a year earlier, driven by continued demand for PEDMARK therapy.

FENC

Stock News•1 months ago

Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth

Fresenius Medical Care's growth potential is tied to new product rollouts and improved patient outcomes. Care Delivery earnings could rise further if outcomes improve, but €80M/quarter CMS incentives ...

FMS

Stock News•1 months ago

Veradermics: VDPHL01 Looks Promising Enough On Paper

Veradermics' VDPHL01 shows encouraging early data for male and female hair loss, but still requires pivotal trial results before potential FDA submission. If approved, it would compete as a cash-pay p...

MANE

Stock News•1 months ago

SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up

SELLAS Life Sciences' Phase 3 REGAL trial for GPS in AML CR2 patients remains an event-driven catalyst. Extended timeline and FDA-approved unlimited dosing add nuance, but only final data will determi...

SLS